Furthermore, multi-target drugs, Tideglusib, Terameprocol, have also undergone clinical trials due to their modulatory function on Nrf2 via GSK-3 inhibition in AD (193), ALS, autism spectrum disorders (194), and CNS cancers (195). Here, NFE2L2 is linked to Alzheimer disease.